Lv1
50 积分 2025-04-01 加入
Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
4个月前
已完结
25P Patient-reported outcomes (PROs) with coformulated vibostolimab/pembrolizumab (vibo/pembro) for metastatic cervical cancer (CC): Results from the KEYVIBE-005 study
4个月前
已完结
Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311)
4个月前
已完结
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
4个月前
已完结
皖公网安备34019202002308
